US5597809A
(en)
*
|
1994-06-23 |
1997-01-28 |
Massachusetts Eye & Ear Infirmary |
Treatment of optic neuritis
|
US5710165A
(en)
*
|
1994-07-06 |
1998-01-20 |
Synthelabo |
Use of polyamine antagonists for the treatment of glaucoma
|
AU716577B2
(en)
*
|
1994-07-06 |
2000-03-02 |
Sanofi-Aventis |
Use of polyamine antagonists for the treatment of glaucoma
|
JPH08231400A
(ja)
*
|
1995-02-24 |
1996-09-10 |
Rohto Pharmaceut Co Ltd |
イフェンプロジルを必須成分とする眼圧降下剤
|
JPH0967270A
(ja)
*
|
1995-08-31 |
1997-03-11 |
Res Dev Corp Of Japan |
水晶体混濁の予防および治療法、並びにそのための薬 剤
|
AU704938B2
(en)
*
|
1995-11-17 |
1999-05-06 |
Alcon Laboratories, Inc. |
Combination therapy for treating glaucoma
|
US6441047B2
(en)
*
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
US5780450A
(en)
*
|
1995-11-21 |
1998-07-14 |
Alcon Laboratories, Inc. |
Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
|
US5965534A
(en)
*
|
1995-11-22 |
1999-10-12 |
Alcon Laboratories, Inc. |
Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
|
AU720326B2
(en)
|
1995-12-21 |
2000-05-25 |
Alcon Laboratories, Inc. |
Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
|
ZA9610745B
(en)
*
|
1995-12-22 |
1997-06-24 |
Warner Lambert Co |
4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
|
ZA9610738B
(en)
|
1995-12-22 |
1997-06-24 |
Warner Lambert Co |
Subtype selective nmda receptor ligands and the use thereof
|
ZA9610741B
(en)
|
1995-12-22 |
1997-06-24 |
Warner Lambert Co |
4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
|
ZA9610736B
(en)
*
|
1995-12-22 |
1997-06-27 |
Warner Lambert Co |
2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
|
CA2241913A1
(en)
*
|
1996-01-02 |
1997-07-10 |
Synthelabo |
Use of polyamine site antagonist for the manufacture of a medicament for the treatment of ischemic disorders of the eye
|
WO1997033582A1
(fr)
*
|
1996-03-14 |
1997-09-18 |
Synthelabo |
Compositions d'antagonistes de site polyamine
|
US5891871A
(en)
*
|
1996-03-21 |
1999-04-06 |
Cocensys, Inc. |
Substituted 2,3-benzodiazepin-4-ones and the use thereof
|
WO1997040834A1
(fr)
*
|
1996-04-26 |
1997-11-06 |
Fujisawa Pharmaceutical Co., Ltd. |
Agents ameliorant la circulation peripherique pour tissus ophthalmiques contenant des dihydropyridines
|
US5891885A
(en)
*
|
1996-10-09 |
1999-04-06 |
Algos Pharmaceutical Corporation |
Method for treating migraine
|
CA2270119A1
(en)
*
|
1996-10-28 |
1998-05-07 |
Senju Pharmaceutical Co., Ltd. |
Drugs for ameliorating ocular circulatory disorders
|
PT946157E
(pt)
*
|
1996-12-16 |
2002-07-31 |
Alcon Lab Inc |
Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular
|
WO1999000129A1
(en)
|
1997-06-30 |
1999-01-07 |
Dreyer Evan B |
Calcium blockers to treat proliferative vitreoretinopathy
|
JP2001515013A
(ja)
*
|
1997-08-14 |
2001-09-18 |
デパートメント オブ ジ アーミー, ユー.エス. ガバメント |
網膜病変および脊髄傷害の処置または予防
|
AU1388999A
(en)
*
|
1997-12-16 |
1999-07-05 |
Alcon Laboratories, Inc. |
The use of nitric oxide generations for the treatment of dry eye disorders
|
JP2002503692A
(ja)
*
|
1998-02-23 |
2002-02-05 |
藤沢薬品工業株式会社 |
マクロライド系化合物の緑内障治療用途
|
JP2002505288A
(ja)
|
1998-03-02 |
2002-02-19 |
コセンシス,インコーポレイテッド |
置換キナゾリンおよびアナログならびにそれらの使用
|
AU5251999A
(en)
|
1998-08-04 |
2000-02-28 |
Wisconsin Alumni Research Foundation |
Method of reducing retinal ganglion cell degeneration
|
US6864232B1
(en)
|
1998-12-24 |
2005-03-08 |
Sucampo Ag |
Agent for treating visual cell function disorder
|
JP2002542150A
(ja)
*
|
1998-12-24 |
2002-12-10 |
株式会社アールテック・ウエノ |
視細胞機能障害処置剤
|
WO2001010442A1
(fr)
*
|
1999-08-09 |
2001-02-15 |
Fujisawa Pharmaceutical Co., Ltd. |
Inhibiteurs de la mort de cellules ganglionnaires de la retine
|
US6174878B1
(en)
|
1999-08-31 |
2001-01-16 |
Alcon Laboratories, Inc. |
Topical use of kappa opioid agonists to treat otic pain
|
AU784347B2
(en)
*
|
1999-11-12 |
2006-03-16 |
Alcon Inc. |
Neurophilin ligands for treating ocular conditions
|
WO2001041756A2
(en)
*
|
1999-12-02 |
2001-06-14 |
University Of South Florida |
Method and composition for treatment of ischemic neuronal reperfusion injury
|
AU2001228863A1
(en)
*
|
2000-01-31 |
2001-08-14 |
Santen Pharmaceutical Co. Ltd. |
Remedies for ophthalmic diseases
|
US6444702B1
(en)
|
2000-02-22 |
2002-09-03 |
Neuromolecular, Inc. |
Aminoadamantane derivatives as therapeutic agents
|
AU4176801A
(en)
*
|
2000-02-29 |
2001-09-12 |
Alcon Lab Inc |
Diagnostics and therapeutics for glaucoma
|
US6956036B1
(en)
|
2000-03-17 |
2005-10-18 |
Alcon, Inc. |
6-hydroxy-indazole derivatives for treating glaucoma
|
US7012090B1
(en)
|
2000-03-17 |
2006-03-14 |
Alcon, Inc. |
Pyranoindoles for treating glaucoma
|
US7005443B1
(en)
|
2000-03-17 |
2006-02-28 |
Alcon, Inc. |
5-Hydroxy indazole derivatives for treating glaucoma
|
US6806285B1
(en)
|
2000-03-17 |
2004-10-19 |
Alcon, Inc. |
5-Hydroxyl indole derivatives for treating glaucoma
|
US6660870B1
(en)
|
2000-03-17 |
2003-12-09 |
Alcon, Inc. |
2-acylaminobenzimidazole derivatives for treating glaucoma
|
US6927233B1
(en)
|
2000-03-17 |
2005-08-09 |
Alcon, Inc. |
5ht2 agonists for controlling IOP and treating glaucoma
|
WO2001092267A2
(en)
*
|
2000-05-30 |
2001-12-06 |
Ortho-Mcneil Pharmaceutical, Inc. |
Dihydropyridine compounds for the inhibition of calcium-influx
|
CA2416169C
(en)
|
2000-07-14 |
2008-09-23 |
Allergan, Inc. |
Compositions containing therapeutically active components having enhanced solubility
|
AU2002214332A1
(en)
*
|
2000-11-22 |
2002-06-03 |
Mitsubishi Pharma Corporation |
Ophthalmological preparations
|
FR2822706A1
(fr)
*
|
2001-03-29 |
2002-10-04 |
Univ Pasteur |
Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
|
US6583152B2
(en)
*
|
2001-04-30 |
2003-06-24 |
Dexgen Pharmaceuticals, Inc. |
Composition for reducing the risk or progression of cardiovascular diseases
|
WO2002098860A1
(en)
|
2001-06-01 |
2002-12-12 |
Alcon, Inc. |
Novel fused indazoles and indoles and their use for the treatment of glaucoma
|
MXPA03010807A
(es)
|
2001-06-01 |
2004-11-22 |
Alcon Inc |
Piranoidazoles y su uso para el tratamiento del glaucoma.
|
CN1512879A
(zh)
|
2001-06-01 |
2004-07-14 |
�Ƹ��� |
新的芳氨基丙烷类似物及其用于治疗青光眼的用途
|
JP4766875B2
(ja)
|
2002-06-06 |
2011-09-07 |
メルク フロスト カナダ リミテツド |
Ep4受容体作動薬、組成物及びその方法
|
US8557855B2
(en)
*
|
2002-07-03 |
2013-10-15 |
Allergan, Inc. |
Methods of using ryanodine antagonists in treating neural injury
|
US7086532B2
(en)
*
|
2003-07-16 |
2006-08-08 |
Allergan, Inc. |
Titration/compliance pack with increasing doses
|
US7196082B2
(en)
|
2002-11-08 |
2007-03-27 |
Merck & Co. Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US7528163B2
(en)
|
2002-11-08 |
2009-05-05 |
Merck & Co. Inc. |
Ophthalmic compositions for treating ocular hypertension
|
US7053085B2
(en)
|
2003-03-26 |
2006-05-30 |
Merck & Co. Inc. |
EP4 receptor agonist, compositions and methods thereof
|
MXPA05006277A
(es)
|
2002-12-13 |
2005-09-08 |
Alcon Inc |
Analogos de benzopirano novedosos y su uso para el tratamiento de glaucoma.
|
AU2003297363A1
(en)
*
|
2002-12-23 |
2004-07-22 |
Alcon, Inc. |
Use of cathepsin k inhibitors for the treatment of glaucoma
|
WO2004069275A1
(ja)
*
|
2003-02-04 |
2004-08-19 |
Mitsubishi Pharma Corporation |
眼科用剤
|
US20050147584A1
(en)
*
|
2004-01-05 |
2005-07-07 |
Allergan, Inc. |
Compositions and methods comprising memantine and polyanionic polymers
|
US20050031652A1
(en)
*
|
2003-02-25 |
2005-02-10 |
Allergan, Inc. |
Compositions and methods comprising memantine and polyanionic polymers
|
US20040191332A1
(en)
*
|
2003-03-27 |
2004-09-30 |
Allergan, Inc. |
Preserved ophthalmic compositions
|
KR101096528B1
(ko)
|
2003-04-17 |
2011-12-20 |
토야마 케미칼 컴퍼니 리미티드 |
알킬에테르 유도체 또는 그 염을 함유하는 망막신경질환의예방·치료제
|
PL1654002T5
(pl)
*
|
2003-08-07 |
2014-06-30 |
Allergan Inc |
Kompozycje do dostarczania środków terapeutycznych do oczu
|
CA2537119A1
(en)
|
2003-09-02 |
2005-03-10 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
CN1842335A
(zh)
|
2003-09-04 |
2006-10-04 |
默克公司 |
用于治疗高眼压的眼用组合物
|
EP1663987B1
(de)
|
2003-09-04 |
2009-03-18 |
Merck & Co., Inc. |
Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US7476687B2
(en)
|
2003-11-26 |
2009-01-13 |
Alcon, Inc. |
Substituted furo[2,3-g]indazoles for the treatment of glaucoma
|
AR046890A1
(es)
|
2003-12-15 |
2005-12-28 |
Alcon Inc |
[1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
|
US7129257B1
(en)
|
2003-12-15 |
2006-10-31 |
Alcon, Inc. |
Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
|
US7338972B1
(en)
|
2003-12-15 |
2008-03-04 |
Alcon, Inc. |
Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
|
US20050277698A1
(en)
*
|
2004-01-05 |
2005-12-15 |
Hughes Patrick M |
Memantine delivery to the back of the eye
|
AU2005209201B2
(en)
|
2004-01-20 |
2010-06-03 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US8512738B2
(en)
|
2004-04-30 |
2013-08-20 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase implants
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
US7799336B2
(en)
*
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
BRPI0513243B8
(pt)
*
|
2004-07-12 |
2021-05-25 |
Allergan Inc |
composições oftálmicas e respectivos usos
|
EP1771170A4
(de)
|
2004-07-20 |
2009-07-08 |
Merck & Co Inc |
Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
|
US20080033053A1
(en)
*
|
2004-07-22 |
2008-02-07 |
Wolfgang Curt D |
Cross-Reference To Related Applications
|
JP2008507588A
(ja)
*
|
2004-07-26 |
2008-03-13 |
アラーガン、インコーポレイテッド |
眼の病態を処置する方法
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
US7425572B2
(en)
|
2004-12-08 |
2008-09-16 |
Alcon, Inc. |
Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
|
WO2006122054A1
(en)
*
|
2005-05-06 |
2006-11-16 |
Chevron U.S.A. Inc. |
Diamondoid derivatives possessing therapeutic activity
|
US20080009546A1
(en)
*
|
2005-05-06 |
2008-01-10 |
Chevron U.S.A. Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
|
CA2608476A1
(en)
*
|
2005-06-28 |
2007-01-04 |
Bausch & Lomb Incorporated |
Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
|
US20070167527A1
(en)
*
|
2006-01-13 |
2007-07-19 |
Burke James A |
Memantine for the normalization of visual acuity deficits
|
WO2007097205A1
(ja)
*
|
2006-02-02 |
2007-08-30 |
Kenji Yoshida |
点眼剤
|
TWI417095B
(zh)
|
2006-03-15 |
2013-12-01 |
Janssen Pharmaceuticals Inc |
1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
UY30883A1
(es)
|
2007-01-31 |
2008-05-31 |
Alcon Res |
Tapones punctales y metodos de liberacion de agentes terapeuticos
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
TW200845978A
(en)
*
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
AU2008297877C1
(en)
*
|
2007-09-14 |
2013-11-07 |
Addex Pharma S.A. |
1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
|
EP2200985B1
(de)
|
2007-09-14 |
2011-07-13 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin-2-one
|
CN101801951B
(zh)
|
2007-09-14 |
2013-11-13 |
杨森制药有限公司 |
1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
|
CN101861316B
(zh)
*
|
2007-11-14 |
2013-08-21 |
奥梅-杨森制药有限公司 |
咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
|
US9192571B2
(en)
*
|
2008-03-03 |
2015-11-24 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
US7842714B2
(en)
|
2008-03-03 |
2010-11-30 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating ocular pain
|
ES2439291T3
(es)
|
2008-09-02 |
2014-01-22 |
Janssen Pharmaceuticals, Inc. |
Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
|
JP5656848B2
(ja)
|
2008-10-16 |
2015-01-21 |
ジャンセン ファーマシューティカルズ, インコーポレイテッド. |
代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
|
US8691813B2
(en)
|
2008-11-28 |
2014-04-08 |
Janssen Pharmaceuticals, Inc. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
EA201101307A1
(ru)
*
|
2009-03-10 |
2012-03-30 |
Сантен Фармасьютикал Ко., Лтд. |
Профилактические или терапевтические средства для расстройств зрительного нерва, содержащие производные 4,6-дихлор-1н-индол-2-карбоновой кислоты или их соли в качестве активных ингредиентов
|
WO2010112615A1
(en)
|
2009-04-03 |
2010-10-07 |
Dsm Ip Assets B.V. |
Lysine derivatives functionalised with lipids
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
MX2011011962A
(es)
|
2009-05-12 |
2012-02-28 |
Janssen Pharmaceuticals Inc |
Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
|
ME01573B
(me)
|
2009-05-12 |
2014-09-20 |
Addex Pharma Sa |
DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
|
US8829020B2
(en)
|
2009-07-16 |
2014-09-09 |
Mallinckrodt Llc |
Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
|
WO2011028797A2
(en)
*
|
2009-09-01 |
2011-03-10 |
Lazarus Therapeutics, Inc. |
Treatment of glaucoma and other retinopathies with gangliosides
|
ES2581523T3
(es)
|
2009-09-01 |
2016-09-06 |
Lz Therapeutics, Inc. |
Producción en cultivo celular (no bovino, no porcino) de GM1
|
KR101769637B1
(ko)
|
2009-11-09 |
2017-08-18 |
알러간, 인코포레이티드 |
모발 성장을 촉진하기 위한 조성물 및 방법
|
KR20130092957A
(ko)
|
2010-04-07 |
2013-08-21 |
알러간, 인코포레이티드 |
안과용 처방용 보존제 조성물의 조합
|
JP2013523828A
(ja)
|
2010-04-07 |
2013-06-17 |
アラーガン インコーポレイテッド |
眼科用組成物のための保存剤の組み合わせ
|
JP5562716B2
(ja)
*
|
2010-05-12 |
2014-07-30 |
花王株式会社 |
電位依存性カチオンチャネル抑制剤
|
US9271967B2
(en)
|
2010-11-08 |
2016-03-01 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
|
JP5852666B2
(ja)
|
2010-11-08 |
2016-02-03 |
ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド |
1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
|
AU2011328195B2
(en)
|
2010-11-08 |
2015-04-02 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
|
EP2602654B1
(de)
*
|
2011-12-08 |
2023-04-19 |
Essilor International |
Ophthalmischer Filter
|
US9556467B2
(en)
|
2012-01-20 |
2017-01-31 |
Garnet Bio Therapeutics, Inc. |
Methods of ganglioside production
|
BR112015019546A2
(pt)
|
2013-02-15 |
2017-07-18 |
Allergan Inc |
implante de distribuição de drogas prolongado
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
PL3096790T3
(pl)
|
2014-01-21 |
2020-01-31 |
Janssen Pharmaceutica, N.V. |
Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
|
KR20200036063A
(ko)
|
2014-01-21 |
2020-04-06 |
얀센 파마슈티카 엔.브이. |
대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
|
EP3223793B1
(de)
|
2014-11-25 |
2023-06-28 |
Eximore Ltd. |
Zusammensetzungen und verfahren zur abgabe eines bioaktiven wirkstoffs oder bioaktiver wirkstoffe
|
US11234897B2
(en)
|
2017-03-27 |
2022-02-01 |
DXM Pharmaceutical, Inc. |
Packaged multi-dose liquid dextromethorphan hydrobromide formulation
|